Core Insights - Tilray Brands (TLRY) is set to report its first-quarter fiscal 2026 results on October 9, 2025, before market opening [1] - The company reported fourth-quarter fiscal 2025 adjusted earnings of 2 cents per share, exceeding the Zacks Consensus Estimate by 166.67% [1] - TLRY has beaten earnings estimates in two of the last four quarters and missed in the other two [1] Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues in the upcoming quarter is $206.8 million, indicating a 3.4% increase from the previous year [2] - The loss per share estimate is set at 3 cents, reflecting a 25% year-over-year increase [2] - Estimates for loss per share have remained unchanged at 3 cents over the past 30 days [3] Factors Influencing Performance - **Cannabis Segment**: In the fourth quarter of fiscal 2025, cannabis net revenues declined year-over-year due to a pause in vape and infused pre-roll categories and delays in international medical cannabis permits. However, international cannabis revenues reached a record high of $22.4 million, with Germany showing 134% growth [4] - **Tilray Medical**: The division introduced three new medical cannabis flower varieties in Italy, becoming the first authorized company to import and distribute its products there. A strategic partnership with Molteni aims to enhance the availability of Tilray Medical cannabis extracts in Italy, expected to boost top-line growth [5] Segment Performance Expectations - **Beverages**: The Beverages segment is anticipated to see a revenue decline due to SKU rationalization under Project 420. However, the Breckenridge Distillery brand is expected to show resilience in the bourbon sector [8][10] - **Wellness**: The Wellness segment is projected to experience a year-over-year revenue surge, driven by the growth of Manitoba Harvest Hemp Hearts and new product innovations [11] - **Distribution**: Distribution revenues, primarily from Tilray Pharma, are expected to grow due to changes in product mix [12] Earnings Outlook - Tilray Brands has an Earnings ESP of 0.00%, indicating no expected earnings surprise for the upcoming report [13] - The company currently holds a Zacks Rank of 3, suggesting a neutral outlook [13]

Core Insights - Breckenridge Distillery has launched Mock One, a new line of non-alcoholic spirits crafted to deliver the complexity and depth of traditional spirits without alcohol [1][4][7] - Mock One is designed for health-conscious consumers and mindful drinkers, offering sophisticated options for crafted cocktails [3][4][7] Product Details - Mock One includes expressions inspired by whiskey, gin, tequila, and rum, featuring bold and nuanced flavor profiles [7] - The tasting notes for Mock One products include: - Mock One Whiskey: oak, cinnamon, vanilla bean, honey [6] - Mock One Gin: juniper, Meyer lemon, kaffir lime, lavender [6] - Mock One Tequila: agave, vanilla bean, honey capsaicin [6] - Mock One Rum: vanilla bean, brown sugar, cola nut, oak [6] Market Availability - Mock One is currently available in Colorado retailers and online nationwide, with plans for broader retail distribution this fall [4][7] Company Background - Breckenridge Distillery, founded in 2008, is known for its award-winning blended bourbon whiskey and has received numerous accolades, including nine Icons of Whisky awards [1][10][12]